Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Francesco Paolo Tambaro, Danilo De Novellis & William G Wierda. (2021) The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. Journal of Experimental Pharmacology 13, pages 923-935.
Read now
Read now
Emeline de Viron, Lucienne Michaux, Natalie Put, Françoise Bontemps & Eric van den Neste. (2012) Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia. Leukemia & Lymphoma 53:8, pages 1445-1451.
Read now
Read now
Lukáš Smolej. (2012) The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 21:7, pages 1009-1017.
Read now
Read now
Jun Ho Yi, Seok Jin Kim, Young Hyeh Ko & Won Seog Kim. (2011) Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leukemia & Lymphoma 52:2, pages 317-320.
Read now
Read now
Articles from other publishers (24)
Yordan Sbirkov, Bozhidar Vergov, Nikolay Mehterov & Victoria Sarafian. (2022) miRNAs in Lymphocytic Leukaemias—The miRror of Drug Resistance. International Journal of Molecular Sciences 23:9, pages 4657.
Crossref
Crossref
Danilo De Novellis, Fabiana Cacace, Valeria Caprioli, William G. Wierda, Kris M. Mahadeo & Francesco Paolo Tambaro. (2021) The TKI Era in Chronic Leukemias. Pharmaceutics 13:12, pages 2201.
Crossref
Crossref
A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes, H Dreau, J Taylor, S J L Knight, R Mansson, D Bentley, R Beekman, J I Martín-Subero, E Campo, R S Houlston, K E Ridout & A Schuh. (2017) Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups. Leukemia 32:2, pages 332-342.
Crossref
Crossref
Vanessa Zurli, Giuliana Wimmer, Francesca Cattaneo, Veronica Candi, Emanuele Cencini, Alessandro Gozzetti, Donatella Raspadori, Giuseppe Campoccia, Francesca Sanseviero, Monica Bocchia, Cosima Tatiana Baldari & Anna Kabanova. (2017) Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. Blood 130:18, pages 2006-2017.
Crossref
Crossref
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg & Jeanette Lundin. (2016) Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunology, Immunotherapy 66:1, pages 91-102.
Crossref
Crossref
Xiaomei Chen, Wei Xiong & Huiyu Li. (2016) Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia. Oncology Letters 12:6, pages 4937-4948.
Crossref
Crossref
Eliza Starczewska, Maxime Beyaert, Lucienne Michaux, Marie-Christiane Vekemans, Pascale Saussoy, Vanesa Bol, Ainhoa Arana Echarri, Caroline Smal, Eric Van Den Neste & Françoise Bontemps. (2016) Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs. Oncotarget 7:25, pages 38367-38379.
Crossref
Crossref
Giulia Fabbri & Riccardo Dalla-Favera. (2016) The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer 16:3, pages 145-162.
Crossref
Crossref
Christian Prinz, Elena Vasyutina, Gregor Lohmann, Alexandra Schrader, Steffen Romanski, Christoph Hirschhäuser, Petra Mayer, Corazon Frias, Carmen D. Herling, Michael Hallek, Hans-Günther Schmalz, Aram Prokop, Dimitrios Mougiakakos & Marco Herling. (2015) Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Molecular Cancer 14:1.
Crossref
Crossref
J Liu, G Chen, L Feng, W Zhang, H Pelicano, F Wang, M A Ogasawara, W Lu, H M Amin, C M Croce, M J Keating & P Huang. (2013) Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cells. Leukemia 28:1, pages 118-128.
Crossref
Crossref
XIANG-XIANG ZHOU & XIN WANG. (2013) Role of microRNAs in chronic lymphocytic leukemia (Review). Molecular Medicine Reports 8:3, pages 719-725.
Crossref
Crossref
Reem Karmali, Laura A Paganessi, Robin R Frank, Sucheta Jagan, Melissa L Larson, Parameswaran Venugopal, Stephanie A Gregory & Kent W Christopherson. (2013) Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. Journal of Leukocyte Biology 93:1, pages 161-170.
Crossref
Crossref
Dan A Landau & Catherine J Wu. (2013) Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Medicine 5:5, pages 47.
Crossref
Crossref
Anna SkowronskaAnton ParkerGulshanara AhmedCeri OldreiveZadie DavisSue RichardsMartin DyerEstella MatutesDavid GonzalezA. Malcolm R. TaylorPaul MossPeter ThomasDavid OscierTatjana Stankovic. (2012)
Biallelic
ATM
Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial
. Journal of Clinical Oncology 30:36, pages 4524-4532.
Crossref
Crossref
Stefano Molica. (2012) The initial approach to patients with chronic lymphocytic leukemia diagnosed in day-to-day practice. International Journal of Hematologic Oncology 1:1, pages 47-55.
Crossref
Crossref
S J L Knight, C Yau, R Clifford, A T Timbs, E Sadighi Akha, H M Dréau, A Burns, C Ciria, D G Oscier, A R Pettitt, S Dutton, C C Holmes, J Taylor, J-B Cazier & A Schuh. (2012) Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 26:7, pages 1564-1575.
Crossref
Crossref
Jelena TomicBrian LichtyDavid E. Spaner. (2011) Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 117:9, pages 2668-2680.
Crossref
Crossref
Valentin Goede & Michael Hallek. (2011) Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia. Drugs & Aging 28:3, pages 163-176.
Crossref
Crossref
Irina Idler, Nupur Bhattacharya, Hartmut D?hner, Stephan Stilgenbauer & Daniel Mertens. (2011) Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews 37, pages S2-S7.
Crossref
Crossref
T Zenz, D Vollmer, M Trbusek, J Smardova, A Benner, T Soussi, H Helfrich, M Heuberger, P Hoth, M Fuge, T Denzel, S Häbe, J Malcikova, P Kuglik, S Truong, N Patten, L Wu, D Oscier, R Ibbotson, A Gardiner, I Tracy, K Lin, A Pettitt, S Pospisilova, J Mayer, M Hallek, H Döhner & S Stilgenbauer. (2010) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 24:12, pages 2072-2079.
Crossref
Crossref
Ali Al-Ameri, Mohamad Cherry, Aref Al-Kali & Alessandra Ferrajoli. (2010) The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals 3:10, pages 3258-3274.
Crossref
Crossref
Thorsten ZenzBarbara EichhorstRaymonde BuschTina DenzelSonja HäbeDirk WinklerAndreas BühlerJennifer EdelmannManuela BergmannGeorg HopfingerManfred HenselMichael HallekHartmut DöhnerStephan Stilgenbauer. (2010)
TP53
Mutation and Survival in Chronic Lymphocytic Leukemia
. Journal of Clinical Oncology 28:29, pages 4473-4479.
Crossref
Crossref
Thorsten Zenz, Stefan Fröhling, Daniel Mertens, Hartmut Döhner & Stephan Stilgenbauer. (2010) Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Practice & Research Clinical Haematology 23:1, pages 71-84.
Crossref
Crossref
A Farfsing, F Engel, M Seiffert, E Hartmann, G Ott, A Rosenwald, S Stilgenbauer, H Döhner, M Boutros, P Lichter & A Pscherer. (2009) Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia 23:11, pages 2018-2026.
Crossref
Crossref